McKesson Q1 Beats, Raises FY27 EPS View to $45 High-End
MCK sits 38% above its 52-week low of $637.
Summary
McKesson delivered a strong fiscal Q1, with revenue of $105.38B and adjusted EPS of $9.93, both comfortably ahead of consensus. The company raised its full-year adjusted EPS guidance to $44.20-$45.00, implying 13-15% growth, and boosted the quarterly dividend by 15%. Despite the strong adjusted results, the company revealed a fall in Q1 bottom line on a GAAP basis. Growth was driven by higher prescription volumes and specialty product distribution in the North American Pharmaceutical and Oncology segments. This follows the robust FY26 results and $7.7B buyback authorization announced in May, reinforcing the positive trajectory. The raised outlook and capital returns signal management's confidence in sustained momentum.
At the time of this announcement, MCK was trading at $880.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.7B. The 52-week trading range was $637.00 to $999.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.